Elevance Health Reports Second Quarter 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Elevance (ELV) PT Raised to $585 at RBC Capital
July 18, 2024 6:13 AM EDTRBC Capital analyst Ben Hendrix raised the price target on Elevance (NYSE: ELV) to $585.00 (from $575.00) while maintaining a Outperform rating.
The analyst comments "We believe ELV shares are oversold on known temporary Medicaid mix headwinds (which should ease over the next 612 months) and DCP optics... More
Morgan Stanley Reiterates Overweight Rating on Elevance (ELV)
July 17, 2024 8:28 AM EDTMorgan Stanley analyst Erin Wright reiterated an Overweight rating and $643.00 price target on Elevance (NYSE: ELV).
The analyst comments "Pre-Call View - ELV Shares Should Grind higher on Consolidated MLR Beat: While we await conf. call granularity on underlying cost trends by line of business, however, the... More
Truist Securities Reiterates Buy Rating on Elevance (ELV)
July 17, 2024 8:28 AM EDTTruist Securities analyst David MacDonald reiterated a Buy rating and $620.00 price target on Elevance (NYSE: ELV).
The analyst comments "First Read Solid 2Q With MLR A Bit Better, Strong Growth At Carelon, FY Guidance Reaffirmed. ELV reported solid 2Q results featuring in-line revenues, MLR that was modestly better than our/consensus estimates and adjusted EPS also topped expectations with FY guidance of at least $37.20 reaffirmed. Operating revenue of $43.22B was roughly in-line with our $43.24BE and consensus $43.05B... More
